| Mr Joshua Artery, PT, DPT | |
|
1951 Bluegrass Cir, Cheyenne, WY 82009-7355 | |
| (307) 773-8533 | |
| (307) 635-7578 |
| Full Name | Mr Joshua Artery |
|---|---|
| Gender | Male |
| Speciality | Physical Therapy |
| Experience | 9 Years |
| Location | 1951 Bluegrass Cir, Cheyenne, Wyoming |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1699151779 | NPI | - | NPPES |
| PT-1590 | Other | WY | STATE LICENSE NUMBER |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | PT-1590 (Wyoming) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Orthopaedic And Neurological Rehab Inc | 6507159126 | 524 |
News Archive
Rheumatologists, dermatologists, and patient advocates have come together to publish the first-ever international guidelines for the treatment of psoriatic arthritis, a disease that mainly affects people who have psoriasis but also some people without it.
The opioid epidemic is fueling a steep rise in infection-related stroke hospitalizations, according to preliminary research to be presented in Honolulu at the American Stroke Association's International Stroke Conference 2019, a world premier meeting for researchers and clinicians dedicated to the science and treatment of cerebrovascular disease.
Cempra Pharmaceuticals today announced completion of enrollment of the Phase 2 portion of its Phase 2/3 clinical trial of TAKSTA (sodium fusidate; CEM-102) for the treatment of acute bacterial skin and skin structure infections.
Entelos, Inc. announced today that it has agreed to the terms of a non-exclusive perpetual license to its Metabolism Physiolab platform for Pfizer Inc. The perpetual license will include access for Pfizer to Entelos' PhysioLab Modeler software and its PhysioLab Simulation Server.
Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved NOXAFIL (posaconazole) injection (18 mg/ mL), a new formulation of NOXAFIL for intravenous (IV) use.
› Verified 1 days ago
| Provider Name | Smart Sports Medicine Clinic Pc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1376690214 PECOS PAC ID: 2062317142 Enrollment ID: O20031203000027 |
News Archive
Rheumatologists, dermatologists, and patient advocates have come together to publish the first-ever international guidelines for the treatment of psoriatic arthritis, a disease that mainly affects people who have psoriasis but also some people without it.
The opioid epidemic is fueling a steep rise in infection-related stroke hospitalizations, according to preliminary research to be presented in Honolulu at the American Stroke Association's International Stroke Conference 2019, a world premier meeting for researchers and clinicians dedicated to the science and treatment of cerebrovascular disease.
Cempra Pharmaceuticals today announced completion of enrollment of the Phase 2 portion of its Phase 2/3 clinical trial of TAKSTA (sodium fusidate; CEM-102) for the treatment of acute bacterial skin and skin structure infections.
Entelos, Inc. announced today that it has agreed to the terms of a non-exclusive perpetual license to its Metabolism Physiolab platform for Pfizer Inc. The perpetual license will include access for Pfizer to Entelos' PhysioLab Modeler software and its PhysioLab Simulation Server.
Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved NOXAFIL (posaconazole) injection (18 mg/ mL), a new formulation of NOXAFIL for intravenous (IV) use.
› Verified 1 days ago
| Provider Name | Smart Sports Medicine Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1114408739 PECOS PAC ID: 5597002857 Enrollment ID: O20190124000222 |
News Archive
Rheumatologists, dermatologists, and patient advocates have come together to publish the first-ever international guidelines for the treatment of psoriatic arthritis, a disease that mainly affects people who have psoriasis but also some people without it.
The opioid epidemic is fueling a steep rise in infection-related stroke hospitalizations, according to preliminary research to be presented in Honolulu at the American Stroke Association's International Stroke Conference 2019, a world premier meeting for researchers and clinicians dedicated to the science and treatment of cerebrovascular disease.
Cempra Pharmaceuticals today announced completion of enrollment of the Phase 2 portion of its Phase 2/3 clinical trial of TAKSTA (sodium fusidate; CEM-102) for the treatment of acute bacterial skin and skin structure infections.
Entelos, Inc. announced today that it has agreed to the terms of a non-exclusive perpetual license to its Metabolism Physiolab platform for Pfizer Inc. The perpetual license will include access for Pfizer to Entelos' PhysioLab Modeler software and its PhysioLab Simulation Server.
Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved NOXAFIL (posaconazole) injection (18 mg/ mL), a new formulation of NOXAFIL for intravenous (IV) use.
› Verified 1 days ago
| Provider Name | Orthopaedic And Neurological Rehab Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1225496540 PECOS PAC ID: 6507159126 Enrollment ID: O20210921001820 |
News Archive
Rheumatologists, dermatologists, and patient advocates have come together to publish the first-ever international guidelines for the treatment of psoriatic arthritis, a disease that mainly affects people who have psoriasis but also some people without it.
The opioid epidemic is fueling a steep rise in infection-related stroke hospitalizations, according to preliminary research to be presented in Honolulu at the American Stroke Association's International Stroke Conference 2019, a world premier meeting for researchers and clinicians dedicated to the science and treatment of cerebrovascular disease.
Cempra Pharmaceuticals today announced completion of enrollment of the Phase 2 portion of its Phase 2/3 clinical trial of TAKSTA (sodium fusidate; CEM-102) for the treatment of acute bacterial skin and skin structure infections.
Entelos, Inc. announced today that it has agreed to the terms of a non-exclusive perpetual license to its Metabolism Physiolab platform for Pfizer Inc. The perpetual license will include access for Pfizer to Entelos' PhysioLab Modeler software and its PhysioLab Simulation Server.
Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved NOXAFIL (posaconazole) injection (18 mg/ mL), a new formulation of NOXAFIL for intravenous (IV) use.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Joshua Artery, PT, DPT 1951 Bluegrass Cir, Cheyenne, WY 82009-7355 Ph: (307) 773-8533 | Mr Joshua Artery, PT, DPT 1951 Bluegrass Cir, Cheyenne, WY 82009-7355 Ph: (307) 773-8533 |
News Archive
Rheumatologists, dermatologists, and patient advocates have come together to publish the first-ever international guidelines for the treatment of psoriatic arthritis, a disease that mainly affects people who have psoriasis but also some people without it.
The opioid epidemic is fueling a steep rise in infection-related stroke hospitalizations, according to preliminary research to be presented in Honolulu at the American Stroke Association's International Stroke Conference 2019, a world premier meeting for researchers and clinicians dedicated to the science and treatment of cerebrovascular disease.
Cempra Pharmaceuticals today announced completion of enrollment of the Phase 2 portion of its Phase 2/3 clinical trial of TAKSTA (sodium fusidate; CEM-102) for the treatment of acute bacterial skin and skin structure infections.
Entelos, Inc. announced today that it has agreed to the terms of a non-exclusive perpetual license to its Metabolism Physiolab platform for Pfizer Inc. The perpetual license will include access for Pfizer to Entelos' PhysioLab Modeler software and its PhysioLab Simulation Server.
Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved NOXAFIL (posaconazole) injection (18 mg/ mL), a new formulation of NOXAFIL for intravenous (IV) use.
› Verified 1 days ago
Bluegrass Physical Therapy Limited Partnership Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1950 Bluegrass Cir, Suite 110, Cheyenne, WY 82009 Phone: 307-634-2626 Fax: 307-634-5099 | |
Mrs. Linda Rc Froelicher, MSPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 4000 Central Ave, Suite #3, Cheyenne, WY 82001 Phone: 307-634-0298 Fax: 307-634-0837 | |
Nicholas Robert Johnson, PT, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1900 Converse Ave Ste B, Cheyenne, WY 82001 Phone: 307-514-2411 Fax: 307-514-2392 | |
Byron Louis Long, MPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1950 Bluegrass Cir, Suite 110, Cheyenne, WY 82009 Phone: 307-634-2626 Fax: 307-634-5099 | |
Mr. Thomas James Bledsoe, M.P.T. Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 4017 Rawlins St, Cheyenne, WY 82001 Phone: 307-635-2562 | |
Sandra Champlin, PT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 1951 Bluegrass Cir, Cheyenne, WY 82009 Phone: 307-773-8533 Fax: 307-635-7578 | |
Dr. Charlene Marie Sheamansmith, PT, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 4515 E Pershing Blvd Unit C, Cheyenne, WY 82001 Phone: 307-635-2388 Fax: 307-635-1730 |